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A B S T R A C T
Objectives: The biochemical serum markers free β-human chorionic gonadotropin (hCGβ) and
pregnancy associated plasma protein A (PAPP-A), used in screening for trisomy 21 (T21), trisomy
18 (T18), and trisomy 13 (T13) during the ﬁrst trimester, can be measured on diﬀerent la-
boratory instruments e.g. Kryptor (Brahms) and Cobas (Roche). We compared the performance of
these two analytical instruments when used for ﬁrst trimester combined testing.
Design and methods: Serum samples from 944 singleton pregnant women attending for ﬁrst tri-
mester combined testing were routinely assayed for hCGβ and PAPP-A on Kryptor, and re-ana-
lyzed on Cobas. In addition, serum samples from 70 pregnant women carrying a fetus aﬀected by
T21, T18 or T13, were re-assayed on Cobas.
Results: For the screening population, the hCGβ and PAPP-A results in multiples of the median
(MoM) from Kryptor and Cobas were signiﬁcantly lower on Cobas when compared to Kryptor.
The number of pregnant women with a risk above 1:300 for T21 was 48 for both Cobas and
Kryptor, although a few patients only had a high risk with one of the methods. Overall, the screen
positive rate was 5.1% for both instruments. In the trisomy groups the calculated risks for T21,
T18, and T13 agreed well between Cobas and Kryptor.
Conclusions: The screen positive rate for T21 (5.1%) did not diﬀer between the two analytical
platforms in our screening population, although PAPP-A measurements form Cobas were sig-
niﬁcantly lower than those from Kryptor. The calculated risks for the pregnancies aﬀected by
trisomies using hCGβ MoM and PAPP-A MoM from Kryptor agreed well with those from Cobas.
1. Introduction
The combined ﬁrst trimester screening program for trisomy 21 (T21), trisomy 18 (T18), and trisomy 13 (T13) in Denmark is based
upon maternal age, measurement of the thickness of fetal nuchal translucency (NT), and the maternal serum concentrations of free β-
human chorionic gonadotrophin (hCGβ), and pregnancy associated plasma protein-A (PAPP-A) [1,2]. The ultrasound measurement
of the NT thickness is performed between 11 + 2 and 14 + 1 weeks of gestation and the biochemical serum markers are measured
from 8 + 1 to 14 + 0 weeks of gestation. hCGβ and PAPP-A concentrations vary during gestation and are therefore converted to
gestational age-adjusted multiples of the median (MoM) values. In all three trisomies, the PAPP-A concentration is decreased, while
hCGβ concentration is usually decreased in T18 and T13, and increased in T21 pregnancies [1]. If the risk is at or above 1:300 for
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T21, or at or above 1:150 for T18 or T13 an invasive diagnostic test (amniocentesis or chorionic villus sampling) is oﬀered [2]. Both
invasive procedures have a risk of fetal loss of 0.5–1.0% [3]. First trimester combined screening for T21 was found to have an average
detection rate of 89.5% with a false positive rate of 3.6% over 2 years [4]. In T18 or T13 the detection rate was found to be 78.8% for
an estimated risk of> 1:150 [2]. Lowering the cut-oﬀ risk threshold would allow more trisomy-aﬀected pregnancies to be detected,
but would also increase the number of false positive pregnancies with increased risk of T21, T18, and T13 leading to increased
numbers of invasive diagnostic tests being oﬀered.
The biochemical analysis of hCGβ and PAPP-A can be performed on diﬀerent analytical systems and it is important not only to
know the analytical variation but also the screen positive rate and the detection rate for these diﬀerent systems. The aim of this study
was to compare the clinical performance of the two analytical instruments, Kryptor and Cobas, in the risk assessment of T21, T18, and
T13 during the ﬁrst trimester.
2. Materials and methods
2.1. Study group - screening population
Data were collected from 1024 pregnant women attending for ﬁrst trimester combined testing at Copenhagen University Hospital
Hvidovre during a two-month period between April 2014 and June 2014. A number of pregnancies (n = 80) were excluded from the
study, due to twin pregnancy (n = 23), missed abortion (n = 8), sample taken outside the screening window (n = 9), lack of a nuchal
translucency scan (n = 36) and other reasons (n = 4). A total of 944 pregnancies were therefore included in the study. The median
maternal age was 31 years (range 17–47 years) and the median gestational age was 11+2 (range 8+1 – 14+0 weeks of gestation) at
time of sampling.
Blood samples were collected into tubes with clot activator and gel separator (4 mL;Greiner Bio-One, Kremsmunster, Austria) and
centrifuged at 1850 g for 10 min within a few hours of collection. Serum was stored at−20 °C until analysis. hCGβ and PAPP-A were
routinely analyzed on the Kryptor system (Thermo Fisher Scientiﬁc, Clinical Diagnostics, Brahms GmbH, Henningsdorf, Germany).
Samples were subsequently stored at – 20 °C for 5–6 months and re-analyzed on Cobas 6000 (Roche Diagnostics, Basel, Switzerland).
The measurement principle of Kryptor is time-resolved ampliﬁed cryptate emission technology while the Cobas employs electro-
chemiluminescence immunoassay.
2.2. Study group - trisomy population
Serum samples from 70 women carrying a fetus aﬀected by T21 (n = 50), T18 (n = 14) or T13 (n = 6) were compared. These
women attended for ﬁrst trimester combined testing at Copenhagen University Hospital Hvidovre between December 2004 and
November 2010.
The median maternal age at time of sampling for T21 pregnancies was 33 years (range 23–44), for T18 pregnancies 37 years
(range 27–43), and for T13 pregnancies 31 years (range 26–40). The median gestational age was 11 + 1 (range 9 + 3 – 13 + 4) for
T21, 10 + 6 (range 9 + 0 – 12 + 5) for T18, and 10 + 6 (range 10 + 2 −11 + 6) for T13 pregnancies.
hCGβ and PAPP-A concentrations were routinely analyzed on Kryptor at the time of testing. After storage at−80 °C, the samples
were re-analyzed on Cobas in the autumn of 2015. The karyotype was determined with either amniocentesis or chorionic villus
sampling or by karyotyping after birth.
2.3. Risk calculation
All measurements of hCGβ and PAPP-A were transformed to multiples of the median (MoM) values for each analytical platform by
a commercial software program and fetal database (Astraia, Gmbh, Munich, Germany) using the latest default medians for the two
instruments. The parameters maternal weight, smoking status, conception method and ethnicity were included in the risk calculation
for T21, T18, and T13.
2.4. Statistical analysis and ethical approval
Data were analyzed using GraphPad Prism, (GraphPad Software, San Diego, CA, USA). We compared the results from Kryptor and
Cobas by plotting the data into a scatter plot and assessing the slopes using Deming and linear regression analysis for MoM and risk
values, respectively. Correlation was measured using nonparametric Spearman r.
The study was conducted following informed consent and was approved by the Danish Data Protection Agency (AHH-2014-014, I-
Suite no 03069).
3. Results
3.1. Screening population
hCGβ MoM and PAPP-A MoM results from Kryptor correlated well with those from Cobas, and the slopes for the regression lines
were 1.04 (95% CI 1.02–1.05) and 0.96 (95% CI 0.94–0.97), respectively (Fig. 1). The median hCGβ MoM was 0.99 for Kryptor and
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0.93 for Cobas. For PAPP-A the median MoM was 0.98 for Kryptor and 0.91 for Cobas. Both hCGβ and PAPP-A MoM values from
Cobas were signiﬁcantly lower when compared to those from Kryptor (p = 0.02 and 0.004, respectively). These diﬀerences can be
seen in the diﬀerence plots (Fig. 2). Further analysis was performed to investigate whether this observed diﬀerence between Kryptor
and Cobas measurements was present at all weeks of gestation by dividing the screening population into subgroups depending on
their week of gestation. Both analytical platforms had low mean log10 hCGβ MoMs and log10 PAPP-A MoMs in weeks 8 and 9 of
gestation, probably because of fewer values (Fig. 3), whereas in weeks 10–12 with more values only log10 PAPP-A MoMs from Cobas
were below 0.
The calculated risks of T21, T18, and T13 in the screening population using results from Kryptor and Cobas agreed well (Fig. 4).
Of 55 pregnancies with a high risk for T21, 41 had an increased risk of T21 regardless of whether the samples were analyzed on either
Kryptor or Cobas, seven only had a high-risk pregnancy when measurements from Kryptor were used, and seven only had a high risk
pregnancy when results from Cobas were used. All 55 pregnancies with a high risk for T21 had a normal karyotype determined by
CVS or AC or no sign of T21 after birth. The screen positive rate for T21 was 5.1% for both Kryptor and Cobas (95% CI 3.8–6.7%).
3.2. Trisomy population
hCGβ MoM values from Kryptor agreed with those from Cobas, and the slopes of the regression lines were 0.73 (95% CI
0.47–0.99) for T13 (n = 6), 1.04 (95% CI 0.95–1.12) for T18 (n = 14) and 1.21 (95% CI 1.06–1.35) for T21 (n = 50) (Fig. 5a–c).
PAPP-A MoM values from Kryptor and Cobas agreed much better, and the slopes of the regression lines were 0.97 (95% CI 0.88–1.07)
for T13, 0.99 (95% CI 0.92–1.05) for T18, and 1.04 (95% CI 0.95–1.13) for T21 (Fig. 5d–f).
As with the screening population, we also compared the calculated risk for T21, T18, and T13 in the three trisomy groups using
results from Kryptor and Cobas. These also agreed well (Fig. 6a–c).
In evaluating the clinical performance in detection of trisomy positive pregnancies, two out of six T13 pregnancies were not
detected by either Kryptor or Cobas when serum markers were included in the ﬁrst trimester combined test with NT thickness and
maternal age. However, both analytical instruments picked up these two T13 pregnancies as the results corresponded to a high risk
for T18. Three out of 14 T18 pregnancies and ﬁve out of 50 T21 pregnancies failed to be identiﬁed using measurements from either
Kryptor or Cobas (the risk values from Kryptor were 1:306, 1:322, 1:593, 1:768, 1:4363).
4. Discussion
We compared hCGβ and PAPP-A MoM values derived from two analytical instruments, Kryptor and Cobas, from pregnant women
in a screening population attending ﬁrst trimester screening for T21, T18, and T13 and in a population of known trisomy pregnancies.
Fig. 1. Comparison plots of hCGβ (a) and PAPP-A (b) MoM values analyzed on Kryptor and Cobas in the screening population (n = 944). The regression lines and
corresponding equations are shown.
Fig. 2. Diﬀerence plot of hCGβ (a) and PAPP-A (b) MoM values for Cobas compared with Kryptor.
A.E. Engell et al. Practical Laboratory Medicine 9 (2017) 18–23
20
In the screening population, both hCGβ and PAPP-A MoM values were lower on Cobas when compared to Kryptor, and these
diﬀerences varied depending on the week of gestation. These results for PAPP-A MoM values are in contrast to a small study by
Hörmansdörfer et al., who obtained PAPP-A MoM values higher on Cobas compared to Kryptor (p<0.0001) [5]. However, similar to
our results, a previous study also found a diﬀerence in hCGβ MoM and PAPP-A MoM values between Kryptor and Cobas in T21
pregnancies in the later weeks of screening gestation (week 10 + 0 to 14 + 0) [6].
In general, one would assume that lower PAPP-A MoM in clinical practice would result in more pregnancies considered to be at
increased risk of trisomy and therefore more invasive diagnostic tests. However, when screening for T21 a corresponding decreased
hCGβ value would result in a reduction in the calculated risk of T21, which might oﬀset the diﬀerences in hCGβ and PAPP-A values.
Furthermore, our study demonstrates that the risk assessment, when including NT and maternal age, is not aﬀected and the same
screen positive rate of 5.1% is found when using results from both analytical instruments.
In the T21 trisomy group a signiﬁcant diﬀerence was found for hCGβMoM values between Kryptor and Cobas (p<0.001) but not
for T18 and T13. Overall, as observed in the screening population, the calculated risk of T21, T18, and T13 agreed well between the
two instruments when the biochemical markers were included in the ﬁrst trimester combined test with NT and maternal age. The two
instruments detected the same number of trisomy pregnancies and each failed to identify the same numbers of false negative cases.
To our knowledge, this is the ﬁrst study comparing samples from T18 and T13 pregnancies on Cobas and Kryptor. A fewer other
studies have compared hCGβ and PAPP-A values measured on Cobas and Kryptor in screening populations, and in T21 aﬀected
Fig. 3. Log10 hCGβ MoM for Kryptor (a) and Cobas (b) and log10 PAPP-A MoM for Kryptor (c) and Cobas (d) in gestational week 8 (n = 9), week 9 (n = 40), week 10
(n = 325), week 11 (n = 350), week 12 (n = 170) and week 13 (n = 50). Means with 95% CI are shown.
Fig. 4. Comparison of the calculated risk of T13 (a), T18 (b), and T21 (c) between Kryptor and Cobas in the screening population (n = 944) using cut-oﬀs of 1:150 for
T13 and T18, and 1:300 for T21.
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pregnancies. Rossier et al. found hCGβ and PAPP-A concentrations to be well-correlated with no signiﬁcant diﬀerence between the
two analytical instruments [7]. The risk of T21 was calculated with two diﬀerent software programs (not Astraia) for a screening
population and T21 pregnancies. Both analytical instruments detected T21 with similar sensitivity and speciﬁcity. Variability in the
results was mostly due to the software, not to the analytical instrument [7].
Other analytical platforms than Kryptor and Cobas exist for measuring hCGβ and PAPP-A in the ﬁrst trimester combined test.
Spencer compared the clinical and analytical performance of the DPC Immulite 2000 with Kryptor by analyzing 813 samples from
normal pregnancies and 60 samples from T21 pregnancies [8]. In that study, Kryptor appeared to give a better clinical performance
than DPC Immulite 2000.
One of the strengths of our study was the homogenous pre-analytical handling of blood samples and data, making the results,
more comparable. The blood samples were all collected and analyzed at the same hospital and laboratory. In addition, the MoM
values and the risk calculations were all generated and performed by the same software program, Astraia, minimizing bias due to
software variation.
A potential limitation of the study is the diﬀerences in storage of the samples. The samples were analyzed prospectively on
Kryptor and retrospectively on Cobas after 5–6 months of storage at−20 °C. However, previous studies about thermal stability have
shown that freezing has no signiﬁcant impact on the stability of hCGβ and PAPP-A [9,10]. By utilizing the latest default medians in
the risk calculation comparisons, this should help eliminate any potential bias from having to use samples frozen for months, or years,
in the retrospective analysis on Cobas.
5. Conclusion
This study demonstrates that although, in our screening population, hCGβ and PAPP-A measurements performed on Cobas were
Fig. 5. Comparison of hCGβ MoM values from Kryptor and Cobas in pregnancies with (a) T13 (n = 6), (b) T18 (n = 14), and (c) T21 (n = 50), and of PAPP-A MoM
values from Kryptor and Cobas in pregnancies with (d) T13 (n = 6), (e) T18 (n = 14), and (f) T21 (n = 50).
Fig. 6. Comparison of the calculated risk for T13 (a), T18 (b), and T21 (c) between Kryptor and Cobas in trisomy aﬀected pregnancies using cut-oﬀs of 1:150 for T13 (n
= 6), T18 (n = 14), and 1:300 for T21 (n = 50).
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signiﬁcantly lower than on Kryptor, the same screen positive rate of 5.1% was found. The two analytical instruments performed
equally well in detecting pregnancies with T21, T18, or T13 karyotypes when hCGβ and PAPP-A were included in the risk calculation.
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